A Review of the Dermatologic Symptoms of Idiopathic Mast Cell Activation Syndrome

February 2019 | Volume 18 | Issue 2 | Original Article | 162 | Copyright © February 2019

Azam A. Qureshi BAa and Adam J. Friedman MDb,c

aUniversity of Maryland School of Medicine, Baltimore, MD bDepartment of Dermatology, George Washington Medical Faculty Associates, Washington, DC cGeorge Washington School of Medicine and Health Sciences, Washington, DC

because of its high estimated prevalence and the diagnostic challenge it presents.9,11,12 Review of the literature conveys thatflushing, pruritus, clotting or bleeding disorders, and dermatographism are the most prominent dermatologic symptoms in iMCAS. Future work should seek to continue to stratify analyses in such a way to compare patients with iMCAS to those with SM and other forms of MCAD in order to determine differences in underlying genetics and clinical presentation. Future studies of iMCAS patients with EDS-like phenotypes are also needed in order to gain further insight regarding the biochemical basis of co-occurring CT abnormalities. As iMCAS is identified with higher acuity, increased understanding of comorbidities and underlying pathophysiology will result and may contribute to the development of improved management of patients suffering.


The authors have no relevant conflicts of interest.


1. Tomioka H, Ishizaka K. Mechanisms of passive sensitization. II. Presence of receptors for IgE on monkey mast cells. J Immunol. 1971;107(4):971-978. http://www.ncbi.nlm.nih.gov/pubmed/4999262. Accessed January 6, 2018.2. Bach MK, Bloch KJ, Austen KF. IgE and IgGa antibody-mediated release of histamine from rat peritoneal cells. I. Optimum conditions for in vitro preparation of target cells with antibody and and challenge with antigen. J Exp Med. 1971;133(4):752-771. http://www.ncbi.nlm.nih.gov/pubmed/4100657. Accessed December 17, 2017.3. Saito H, Ishizaka T, Ishizaka K. Mast Cells and IgE: From history to today. Allergol Int. 2013;62(1):3-12. doi:10.2332/allergolint.13-RAI-0537.4. Moon TC, Befus AD, Kulka M. Mast cell mediators: Their differential release and the secretory pathways involved. Front Immunol. 2014;5:569. doi:10.3389/fimmu.2014.00569.5. Valent P, Akin C, Arock M, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: A consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215- 225. doi:10.1159/000328760.6. Akin C, Valent P, Metcalfe DD. Mast cell activation syndrome: Proposed diagnostic criteria. J Allergy Clin Immunol. 2010;126(6):1099-104.e4. doi:10.1016/j.jaci.2010.08.035.7. Molderings GJ, Kolck UW, Scheurlen C, Bru?ss M, Homann J, Von Ku?gelgen I. Multiple novel alterations in Kit tyrosine kinase in patients with gastrointestinally pronounced systemic mast cell activation disorder. Scand J Gastroenterol. 2007;42(9):1045-1053. doi:10.1080/00365520701245744.8. Afrin LB. The presentation, diagnosis and treatment of mast cell activation syndrome introduction: Emerging appreciation of a much larger spectrum of mast cell disease. Curr Allergy Clin Immunol. 2014;27(3). https://www. allergysa.co.za/Content/Journals/September2014/ThePresentation.pdf. Accessed December 23, 2017.9. Molderings GJ, Haenisch B, Bogdanow M, Fimmers R, Nöthen MM. Familial occurrence of systemic mast cell activation disease. Wallace GR, ed. PLoS One. 2013;8(9):e76241. doi:10.1371/journal.pone.0076241.10. Molderings GJ, Homann J, Raithel M, Frieling T. Toward a global classification of mast cell activation diseases. J Allergy Clin Immunol. 2011;127(5):1311. doi:10.1016/j.jaci.2010.12.1113.11. Haenisch B, Nöthen MM, Molderings GJ. Systemic mast cell activation disease: The role of molecular genetic alterations in pathogenesis, heritability and diagnostics. Immunology. 2012;137(3):197-205. doi:10.1111/j.1365- 2567.2012.03627.x.12. Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: Survival studies and prognostic factors. Blood. 2009;113(23):5727- 5736. doi:10.1182/blood-2009-02-205237.13. Schäfer D, Dreßen P, Brettner S, et al. Prostaglandin D2-supplemented “functional eicosanoid testing and typing” assay with peripheral blood leukocytes as a new tool in the diagnosis of systemic mast cell activation disease: an explorative diagnostic study. J Transl Med. 2014;12(1):213. doi:10.1186/s12967-014-0213-2.14. Afrin LB, Self S, Menk J, Lazarchick J. Characterization of mast cell activation syndrome. Am J Med Sci. 2017;353(3):207-215. doi:10.1016/j.amjms.jms. 2016.12.013.15. Fanning LB, Boyce J a. Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol. 2013;111(3):155-162. doi:10.1016/j.anai.2013.06.031.16. Metcalfe DD, Pawankar R, Ackerman SJ, et al. Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases. World Allergy Organ J. 2016;9(1). doi:10.1186/s40413-016-0094-3.17. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11β-prostaglandin2α. J Allergy Clin Immunol Pract. 2014;2(6):775-778. doi:10.1016/j.jaip.2014.06.011.18. Molderings GJ, Raithel M, Kratz F, et al. Omalizumab treatment of systemic mast cell activation disease: experiences from four cases. Intern Med. 2011;50(6):611-615. http://www.ncbi.nlm.nih.gov/pubmed/21422688. Accessed December 24, 2017.19. Hamilton MJ, Hornick JL, Akin C, Castells MC, Greenberger NJ. Mast cell activation syndrome: a newly recognized disorder with systemic clinical manifestations. J Allergy Clin Immunol. 2011;128(1):147-152.e2. doi:10.1016/j. jaci.2011.04.037.20. Afrin L, Molderings GJ. A concise, practical guide to diagnostic assessment for mast cell activation disease. World J Hematol. 2014;3(1):1-17. doi:10.5315.21. Sperr WR, Jordan JH, Fiegl M, et al. Serum tryptase levels in patients with mastocytosis: Correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol. 2002;128(2):136-141. doi:10.1159/000059404.22. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26(3):451-463. doi:10.1016/j.iac.2006.05.010.23. Valent P, Horny H-P, Triggiani M, Arock M. Clinical and laboratory parameters of mast cell activation as basis for the formulation of diagnostic criteria. Int Arch Allergy Immunol. 2011;156(2):119-127. doi:10.1159/000323763.24. Matito A, Morgado JM, Álvarez-Twose I, et al. Serum tryptase monitoring in indolent systemic mastocytosis: association with disease features and patient outcome. PLoS One. 2013;8(10). doi:10.1371/journal.pone.0076116.25. Afrin LB, Spruill LS, Schabel SI, Young-Pierce JL. Improved metastatic uterine papillary serous cancer outcome with treatment of mast cell activation syndrome. Oncology (Williston Park). 2014;28(2):129-131, 134. http://www. ncbi.nlm.nih.gov/pubmed/24701700. Accessed December 24, 2017.26. Afrin LB. Mast cell activation syndrome as a significant comorbidity in sickle cell disease. Am J Med Sci. 2014;348(6):460-464. doi:10.1097/ MAJ.0000000000000325.27. Cheung I, Vadas P. A new disease cluster: Mast cell activation syndrome, postural orthostatic tachycardia syndrome, and ehlers-danlos syndrome. J Allergy Clin Immunol. 2015;135(2):AB65. doi:10.1016/j.jaci.2014.12.1146.28. Louisias M, Silverman S, Maitland A. Prevalence of allergic disorders and mast cell activation syndrome in patients with Ehlers–Danlos syndrome. Ann Allergy Asthma Immunol. https://www-embase-com.elibrary.einstein.yu.edu/;jsessionid=21582DBFBDC4BB0EF3BDE201D9952CF1#advancedS earch/resultspage/history.1/page.1/25.items/orderby.date/source. Published 2013. Accessed January 5, 2018.29. Molderings GJ, Brettner S, Homann J, Afrin LB. Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic options. J Hematol Oncol. 2011;4(1):10. doi:10.1186/1756-8722-4-10.30. Butterfield JH, Weiler CR. Prevention of mast cell activation disorder-associated clinical sequelae of excessive prostaglandin D(2) production. Int Arch Allergy Immunol. 2008;147(4):338-343. doi:10.1159/000144042.31. Afrin LB. Sclerosing mediastinitis and mast cell activation syndrome. Pathol Res Pract. 2012;208(3):181-185. doi:10.1016/j.prp.2011.12.005.32. Bell MC, Jackson DJ. Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab. Ann Allergy, Asthma Immunol. 2012;108(5):383- 384. doi:10.1016/j.anai.2012.02.021.33. Mönkemu?ller K, Kassalik M, Baraksei D, Fry L, Moege J. Mast cell activation syndrome (MCAS) diagnosed using double-balloon enteroscopy. Endoscopy. 2012;44(S 02):E72-E73. doi:10.1055/s-0031-1291587.34. Afrin LB, Cichocki FM, Patel K, Molderings GJ. Successful treatment of mast cell activation syndrome with sunitinib. Eur J Haematol. 2015;95(6):595-597. doi:10.1111/ejh.12606.35. Afrin LB, Fox RW, Zito SL, Choe L, Glover SC. Successful targeted treatment of mast cell activation syndrome with tofacitinib. Eur J Haematol. 2017;99(2):190-193. doi:10.1111/ejh.12893.36. Molderings GJ, Knu?chel-Clarke R, Hertfelder HJ, Kuhl C. Mast Cell Activation Syndrome Mimicking Breast Cancer: Case Report With Pathophysiologic Considerations. Clinical Breast Cancer. 2018.37. Simpson R, Mair FS, Mercer SW. Mindfulness-based stress reduction for people with multiple sclerosis – a feasibility randomised controlled trial. BMC Neurol. 2017;17(1):94. doi:10.1186/s12883-017-0880-8.38. Patel S V., Baldwin JL. A 60-year-old woman with recurrent episodes of flush